Last reviewed · How we verify
low dose Streptozotocin
Low dose Streptozotocin, marketed by Al-Azhar University, holds a niche position in the pharmaceutical market with its unique mechanism of action. The key composition patent, expiring in 2028, provides a significant period of exclusivity and potential revenue protection. However, the lack of detailed clinical trial results and primary indication data poses a significant risk to its market acceptance and competitive positioning.
At a glance
| Generic name | low dose Streptozotocin |
|---|---|
| Sponsor | Al-Azhar University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low dose Streptozotocin CI brief — competitive landscape report
- low dose Streptozotocin updates RSS · CI watch RSS
- Al-Azhar University portfolio CI